Companies › NuvOx
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NanO2™ (dodecafluoropentane) Perfluorocarbon emulsion oxygen delivery agent; increases oxygen delivery to tumors to enh | – | Phase 2 | Glioblastoma Multiforme; Mild Respiratory Distress | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06658535 | NanO2™ (dodecafluoropentane) | Phase 1 | Mild Respiratory Distress | Respiratory | Dec 2026 |
| NCT03862430 | NanO2™ (dodecafluoropentane) | Phase 2 | Glioblastoma Multiforme | Oncology | Jun 2027 |
No annotated target.
–
SPARK Biopharma MiNK Therapeutics Nanjing RegeneCore Biotech Guangzhou JOYO Pharma Shanghai Guangsheng Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.